Impella devices: a comprehensive review of their development, use, and impact on cardiogenic shock and high-risk percutaneous coronary intervention

References

• Vahdatpour C, Collins D, Goldberg S. Cardiogenic Shock. J Am Heart Assoc. 2019;8(8). doi: 10.1161/JAHA.119.011991
   PubMed Web of Science ®Google Scholar
• Tehrani BN, Truesdell AG, Psotka MA, et al. A standardized and comprehensive approach to the management of cardiogenic shock. JACC Heart Fail. 2020;8(11):879–891. doi: 10.1016/j.jchf.2020.09.005
   PubMed Web of Science ®Google Scholar
• Osman M, Syed M, Patibandla S, et al. Fifteen‐year trends in incidence of cardiogenic shock hospitalization and in‐hospital mortality in the United States. J Am Heart Assoc. 2021;10(15):10. doi: 10.1161/JAHA.121.021061
   Web of Science ®Google Scholar
• Glazier JJ, Kaki A. The impella device: historical background, clinical applications and future directions. Int J Angiology. 2019;28(2):118–123. doi: 10.1055/s-0038-1676369
   PubMed Web of Science ®Google Scholar
• Perera D. Elective Intra-aortic Balloon Counterpulsation During High-Risk Percutaneous Coronary Intervention A Randomized Controlled Trial. JAMA. 2010;304(8):867. doi: 10.1001/jama.2010.1190
   PubMed Web of Science ®Google Scholar
• Thiele H, Zeymer U, Neumann F-J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287–1296. doi: 10.1056/NEJMoa1208410
   PubMed Web of Science ®Google Scholar
• Baldetti L, Pagnesi M, Gramegna M, et al. Intra-aortic balloon pumping in acute decompensated heart failure with hypoperfusion: from pathophysiology to clinical practice. Circ: Heart Failure. 2021;14(11):e008527. doi: 10.1161/CIRCHEARTFAILURE.121.008527
   PubMed Web of Science ®Google Scholar
• Siess T, Nix C, Menzler F. From a lab type to a product: a retrospective view on impella’s assist technology. Artif Organs. 2001;25:414–421. doi: 10.1046/j.1525-1594.2001.025005414.x
   PubMed Web of Science ®Google Scholar
• Bart Meyns JS, Leunens V, Verbeken E, et al. Left ventricular support by Catheter-Mounted axial flow pump reduces infarct size. Journal Of The American College Of Cardiology. 2003;41(7):1087–1095. doi: 10.1016/S0735-1097(03)00084-6
   PubMed Web of Science ®Google Scholar
• Bart Meyns PS, Nishida T, Perek B, et al. Micropumps to support the heart during CABG. Eur J Cardiothorac Surg. 1999;17(2):169–174. doi: 10.1016/S1010-7940(00)00317-1
   Web of Science ®Google Scholar
• Rami Zein CP, Mercado-Alamo A, Schreiber T, et al. A review of the impella devices. Interventional Cardiology: Reviews, Research, Resources. 2022;17:e05. doi: 10.15420/icr.2021.11
   Google Scholar
• Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J Am Coll Cardiol. 2004;44(2):340–348. doi: 10.1016/j.jacc.2004.03.060
   PubMed Web of Science ®Google Scholar
• Roberts N, Chandrasekaran U, Das S, et al. Hemolysis associated with impella heart pump positioning: in vitro hemolysis testing and computational fluid dynamics modeling. Int J Artif Organs. 2020;43(11):710–718. doi: 10.1177/0391398820909843
   Web of Science ®Google Scholar
• Baldetti L, Beneduce A, Romagnolo D, et al. Impella malrotation within the left ventricle is associated with adverse in-hospital outcomes in cardiogenic shock. JACC Cardiovasc Interv. 2023;16(6):739–741. doi: 10.1016/j.jcin.2023.01.020
   PubMed Web of Science ®Google Scholar
• Burkhoff D, Sayer G, Doshi D, et al. Hemodynamics of mechanical circulatory support. J Am Coll Cardiol. 2015;66(23):2663–2674. doi: 10.1016/j.jacc.2015.10.017
   PubMed Web of Science ®Google Scholar
• Levine A, Kai M, Ohira S, et al. Ecpella 5.5: an evolution in the management of mechanical circulatory support. Cardiol Rev. 2022; Publish Ahead of Print. doi: 10.1097/CRD.0000000000000466
   PubMedGoogle Scholar
• Dixon SR, Henriques JPS, Mauri L, et al. A Prospective feasibility trial investigating the use of the impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (the protect i trial): initial U.S. experience. JACC Cardiovasc Interv. 2009;2(2):91–96. doi: 10.1016/j.jcin.2008.11.005
   PubMed Web of Science ®Google Scholar
• O’Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention. Circulation. 2012;126(14):1717–1727. doi: 10.1161/CIRCULATIONAHA.112.098194
   PubMed Web of Science ®Google Scholar
• O’Neill WW, Schreiber T, Wohns DHW, et al. The current use of impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the uspella registry. J Int Cardiol. 2014;27(1):1–11. doi: 10.1111/joic.12080
   PubMed Web of Science ®Google Scholar
• Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584–1588. doi: 10.1016/j.jacc.2008.05.065
   PubMed Web of Science ®Google Scholar
• Ouweneel DM, Engstrom AE, Sjauw KD, et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. Int J Cardiol. 2016;202:894–896. doi: 10.1016/j.ijcard.2015.10.063
   PubMed Web of Science ®Google Scholar
• Manzo-Silberman S, Fichet J, Mathonnet A, et al. Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and IMPELLA Recover LP2.5. Resuscitation. 2013;84(5):609–615. doi: 10.1016/j.resuscitation.2012.10.001
   PubMed Web of Science ®Google Scholar
• Cena M, Karam F, Ramineni R, et al. New impella cardiac power device used in patient with cardiogenic shock due to nonischemic cardiomyopathy. Int J Angiol. 2016;25(4):258–262. doi: 10.1055/s-0034-1384822
   PubMedGoogle Scholar
• Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69(3):278–287. doi: 10.1016/j.jacc.2016.10.022
   PubMed Web of Science ®Google Scholar
• Basir MB, Schreiber T, Dixon S, et al. Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: The Detroit cardiogenic shock initiative. Catheter Cardiovasc Interv. 2018;91(3):454–461. doi: 10.1002/ccd.27427
   PubMed Web of Science ®Google Scholar
• O’Neill W. Updates from the national cardiogenic shock initiative. Interventional Cardol Rev. 2021;16(Suppl 2):11–12.
   Google Scholar
• O’Neill WW, Grines C, Schreiber T, et al. Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device. Am Heart J. 2018;202:33–38. doi: 10.1016/j.ahj.2018.03.024
   PubMed Web of Science ®Google Scholar
• Udesen NJ, Møller JE, Lindholm MG, et al. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. Am Heart J. 2019;214:60–68. doi: 10.1016/j.ahj.2019.04.019
   PubMed Web of Science ®Google Scholar
• Møller JE, Kjaergaard J, Terkelsen CJ, et al. Impella to treat acute myocardial infarct-related cardiogenic shock. J Clin Med. 2022;11(9):11. doi: 10.3390/jcm11092427
   Web of Science ®Google Scholar
• Griffith BP, Anderson MB, Samuels LE, et al. The RECOVER I: A multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiovasc Surg. 2013;145(2):548–554. doi: 10.1016/j.jtcvs.2012.01.067
   PubMed Web of Science ®Google Scholar
• Ramzy D, Soltesz E, Anderson M. New surgical circulatory support system outcomes. Asaio J. 2020;66(7):746–752. doi: 10.1097/MAT.0000000000001194
   PubMed Web of Science ®Google Scholar
• Ohira S, Pan S, Levine A, et al. High flow from Impella 5.5 with partial veno-arterial extracorporeal membrane oxygenation support: case series. Artif Organs. 2022;46(6):1198–1203. doi: 10.1111/aor.14183
   PubMed Web of Science ®Google Scholar
• de Armas I S, Bergeron A, Bhardwaj A, et al. Surgically implanted impella device for patients on impella CP support experiencing refractory hemolysis. Asaio J. 2022;68(12):e251–e255. doi: 10.1097/MAT.0000000000001712
   PubMed Web of Science ®Google Scholar
• Ramzy D, Anderson M, Batsides G, et al. Early outcomes of the first 200 US patients treated with impella 5.5: a novel temporary left ventricular assist device. Innovations (Phila). 2021;16(4):365–372. doi: 10.1177/15569845211013329
   PubMedGoogle Scholar
• Funamoto M, Kunavarapu C, Kwan MD, et al. Single center experience and early outcomes of Impella 5.5. Front Cardiovasc Med. 2023;10:1018203. doi: 10.3389/fcvm.2023.1018203
   PubMed Web of Science ®Google Scholar
• Keebler ME, Haddad EV, Choi CW, et al. Venoarterial extracorporeal membrane oxygenation in cardiogenic shock. JACC Heart Fail. 2018;6(6):503–516. doi: 10.1016/j.jchf.2017.11.017
   PubMed Web of Science ®Google Scholar
• Russo JJ, Aleksova N, Pitcher I, et al. Left Ventricular Unloading During Extracorporeal Membrane Oxygenation in Patients with Cardiogenic Shock. J Am Coll Cardiol. 2019;73(6):654–662. doi: 10.1016/j.jacc.2018.10.085
   PubMed Web of Science ®Google Scholar
• Baldetti L, Gramegna M, Beneduce A, et al. Strategies of left ventricular unloading during VA-ECMO support: a network meta-analysis. Int J Cardiol. 2020;312:16–21. doi: 10.1016/j.ijcard.2020.02.004
   PubMed Web of Science ®Google Scholar
• Isath A, Gass A, Pan S, et al. (227) impella 5.5 with veno-arterial extracorporeal membrane oxygenation support as ecpella 5.5. J Heart Lung Transplant. 2023;42(4):S112. doi: 10.1016/j.healun.2023.02.1531
   Web of Science ®Google Scholar
• Unoki T, Tamura Y, Nakayama T, et al. Combined use of VA-ECMO and IMPELLA (ECPELLA) as a possible strategy to improve outcomes in patients who underwent E-CPR. Eur Heart J. 2020;41(Supplement_2):41. doi: 10.1093/ehjci/ehaa946.1861
   Google Scholar
• Rotar EP, Mehaffey JH. Commentary: can we REVERSE the effects of venous-arterial extracorporeal membrane oxygenation in cardiogenic shock? JTCVS Open. 2021;8:403–404. doi: 10.1016/j.xjon.2021.09.006
   PubMedGoogle Scholar
• Pieri M, Pappalardo F. Impella RP in the treatment of right ventricular failure: what we know and where we go. J Cardiothorac Vasc Anesth. 2018;32(5):2339–2343. doi: 10.1053/j.jvca.2018.06.007
   PubMed Web of Science ®Google Scholar
• Han JJ. Impella RP Flex with SmartAssist receives FDA pre-market approval. Artif Organs. 2023;47(1):10–11. doi: 10.1111/aor.14461
   PubMed Web of Science ®Google Scholar
• Anderson MB, Goldstein J, Milano C, et al. Benefits of a novel percutaneous ventricular assist device for right heart failure: the prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant. 2015;34(12):1549–1560. doi: 10.1016/j.healun.2015.08.018
   PubMed Web of Science ®Google Scholar
• Anderson M, Morris DL, Tang D, et al. Outcomes of patients with right ventricular failure requiring short-term hemodynamic support with the Impella RP device. J Heart Lung Transplant. 2018;37(12):1448–1458. doi: 10.1016/j.healun.2018.08.001
   PubMed Web of Science ®Google Scholar
• Pappalardo F, Scandroglio AM, Latib A. Full percutaneous biventricular support with two impella pumps: the Bi-Pella approach. ESC Heart Fail. 2018;5(3):368–371. doi: 10.1002/ehf2.12274
   PubMed Web of Science ®Google Scholar
• Jones TL, Kearney KE, McCabe JM. Prevalence and predictors of vascular thrombus formation after percutaneous axillary artery impella insertion. Circ: Cardiovascular Interventions. 2019;12(8):12. doi: 10.1161/CIRCINTERVENTIONS.119.008046
   Web of Science ®Google Scholar
• Gambaro A, Rosenberg A, Galiatsou E, et al. Pros and cons of different types of mechanical circulatory support device in case of postinfarction ventricular septal defect. Asaio J. 2021;67(6):e110–e113. doi: 10.1097/MAT.0000000000001290
   PubMed Web of Science ®Google Scholar
• Atreya AR, Kawamoto K, Yelavarthy P, et al. Acute myocardial infarction and papillary muscle rupture in the COVID-19 era. JACC Case Rep. 2020;2(10):1637–1641. doi: 10.1016/j.jaccas.2020.06.037
   PubMedGoogle Scholar
• Shewmake A, Cooke R, Exaire J, et al. Prevalence and predictors of hemolysis in patients requiring circulatory support with impella cp percutaneous left ventricular assist device. J Am Coll Cardiol. 2019;73(9):1219–1219. doi: 10.1016/S0735-1097(19)31826-1
   Web of Science ®Google Scholar
• Dhruva SS, Ross JS, Mortazavi BJ, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2020;323(8):734–745. doi: 10.1001/jama.2020.0254
   PubMed Web of Science ®Google Scholar
• Wernly B, Seelmaier C, Leistner D, et al. Mechanical circulatory support with Impella versus intra-aortic balloon pump or medical treatment in cardiogenic shock—a critical appraisal of current data. Clin Res Cardiol. 2019;108(11):1249–1257. doi: 10.1007/s00392-019-01458-2
   PubMed Web of Science ®Google Scholar
• Kummerfeldt CE, Toma A, Badheka AO, et al. Severe hemolytic anemia and acute kidney injury after percutaneous continuous-flow ventricular assistance. Circ: Heart Failure. 2011;4(6):e20–e22. doi: 10.1161/CIRCHEARTFAILURE.111.964023
   PubMed Web of Science ®Google Scholar
• Payne JE, Hodskins E, Gold MR, et al. Pigment nephropathy associated with percutaneous hemodynamic support during ventricular tachycardia ablation. HeartRhythm Case Rep. 2020;6(10):720–723. doi: 10.1016/j.hrcr.2020.06.029
   PubMedGoogle Scholar
• Sef D, Kabir T, Lees NJ, et al. Valvular complications following the Impella device implantation. J Card Surg. 2021;36(3):1062–1066. doi: 10.1111/jocs.15303
   PubMed Web of Science ®Google Scholar
• Rohm CL, Gadidov B, Ray HE, et al. Vasopressors and inotropes as predictors of mortality in acute severe cardiogenic shock treated with the impella device. Cardiovasc Revascularization Med. 2021;31:71–75. doi: 10.1016/j.carrev.2020.12.001
   PubMed Web of Science ®Google Scholar